C
CellMEAT
Aims to provide sustainable meat to the food market to address a global concern on the sustainability of the current production and consumption patterns
About CellMEAT
CellMEAT is a biotechnology startup focused on developing cultured meat, which is meat produced by cultivating animal cells in a controlled environment. The company aims to create a sustainable alternative to traditional meat production, eliminating the need for animal slaughter and significantly reducing the environmental impact associated with livestock farming. CellMEAT serves a diverse range of clients, including food manufacturers, restaurants, and consumers who are looking for ethical and eco-friendly meat options. Operating in the rapidly growing cultured meat market, the company leverages advanced cell biology and molecular biology techniques to produce high-quality meat products. CellMEAT's business model involves research and development, production, and commercialization of cultured meat, generating revenue through product sales and potential partnerships with food industry stakeholders. The company is strategically positioned to capitalize on the increasing demand for sustainable and ethical food sources.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Gwangju, South Korea
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 31.7/100
- Industry
- Food
- Sub-industry
- Innovative Food
- Sector
- Food, Spinout, Alternative Protein, Meat Substitute, Sustainable Development Goals, Lab-Grown, Climate Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | May 2023 | $4.9M | $41M | NH Venture Investment · Daewoodang Healthcare · BNK Venture Investment · Ryu Kyung PSG Asset Management | ↗ |
| SERIES AOther financing | Apr 2022 | $8.1M | $32M | BNK Venture Investment · Ryukyung PSG · Strong Ventures · Nau IB Capital | ↗ |
Growth signals
Latest recorded traffic for CellMEAT is 2.8K monthly website visits, up 86.7% over the last three months. CellMEAT's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
JNU Holdings
DT&Investment
BNK Venture Investment
Nau IB Capital- YHYonsei Technology Holdings
Knollwood Investment Advisory- RMRyu Kyung PSG Asset Management
Series A5 investors entered at this stage
- RPRyukyung PSG
Strong Ventures- NINH Venture Investment
- DHDaewoodang Healthcare
Genting Ventures
Other known investors2 additional known investors
Chungnam National University
Primer
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CellMEAT on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CellMEAT’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.